BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Julphar
Fuji
Boehringer Ingelheim
AstraZeneca
UBS
Harvard Business School
Merck
Covington
Mallinckrodt

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,627,816

« Back to Dashboard

Which drugs does patent 8,627,816 protect, and when does it expire?

Patent 8,627,816 protects EVZIO and is included in two NDAs.

This patent has thirty-one patent family members in ten countries.
Summary for Patent: 8,627,816
Title:Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Abstract: Medicament delivery devices for administration of opioid antagonists are described herein. In some embodiments, an apparatus includes a housing, a medicament container disposed within the housing and an energy storage member disposed within the housing. The medicament container is filled with a naloxone composition that includes naloxone or salts thereof, a tonicity-adjusting agent, and a pH adjusting agent, whereby the osmolality of the naloxone composition ranges from about 250-350 mOsm and the pH ranges from about 3-5. The energy storage member is configured to produce a force to deliver the naloxone composition.
Inventor(s): Edwards; Eric S. (Midlothian, VA), Edwards; Evan T. (Gordonsville, VA), Licata; Mark J. (Doswell, VA), Blondino; Frank E. (Henrico, VA)
Assignee: Intelliject, Inc. (Richmond, VA)
Application Number:13/036,720
Patent Claim Types:
see list of patent claims
Composition; Device; Delivery;

Drugs Protected by US Patent 8,627,816

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Kaleo Inc EVZIO naloxone hydrochloride SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS 205787-001 Apr 3, 2014 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Kaleo Inc EVZIO naloxone hydrochloride SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS 209862-001 Oct 19, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,627,816

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,474,869 Medicament delivery device for administration of opioid antagonists including formulations for naloxone ➤ Subscribe
8,939,943 Medicament delivery device for administration of opioid antagonists including formulations for naloxone ➤ Subscribe
9,022,022 Medicament delivery device for administration of opioid antagonists including formulations for naloxone ➤ Subscribe
9,814,838 Medicament delivery device for administration of opioid antagonists including formulations for naloxone ➤ Subscribe
9,173,999 Devices and methods for delivering medicaments from a multi-chamber container ➤ Subscribe
9,084,849 Medicament delivery devices for administration of a medicament within a prefilled syringe ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,627,816

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Mexico 340676 ➤ Subscribe
Mexico 2013008614 ➤ Subscribe
Mexico 340391 ➤ Subscribe
Mexico 2013008617 ➤ Subscribe
Japan 2014504930 ➤ Subscribe
Japan 6076262 ➤ Subscribe
Japan 2014510560 ➤ Subscribe
Israel 227617 ➤ Subscribe
Israel 227616 ➤ Subscribe
United Kingdom 201316340 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Fish and Richardson
Novartis
Citi
Accenture
Federal Trade Commission
Farmers Insurance
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot